AMERICAN CLINICAL LABORATORY ASSN for AMERICAN CLINICAL LABORATORY ASSN
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 2nd Quarter - Report (this page) | Jul 16, 2025 | $450,000 | Replaced |
| 2nd Quarter - Amendment | Oct 17, 2025 | $510,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medical/Disease Research/Clinical Labs MED
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule; laboratory test coding, pricing, coverage, and payment; implementation of the Protecting Access to Medicare Act (P.L. 113-93); diagnostic regulatory reform; artificial intelligence in laboratory services; utilization management, including prior authorization policies impacting clinical laboratories.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HOLLY GROSHOLZ | — |
| SUSAN VAN METER | — |
| MARY LEE WATTS | — |
Medicare/Medicaid MMM
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule; laboratory test coding, pricing, coverage, and payment; implementation of the Protecting Access to Medicare Act (P.L. 113-93).
| Lobbyist | Covered position, as disclosed |
|---|---|
| HOLLY GROSHOLZ | — |
| SUSAN VAN METER | — |
Health Issues HCR
Reimbursement and coverage issues for and related to clinical laboratory services, including the Medicare clinical laboratory fee schedule; laboratory test coding, pricing, coverage, and payment; implementation of the Protecting Access to Medicare Act (P.L. 113-93); diagnostics regulatory reform; FDA and CMS policies related to diagnostics and laboratory regulation; price transparency requirements for clinical laboratory services.
| Lobbyist | Covered position, as disclosed |
|---|---|
| HOLLY GROSHOLZ | — |
| SUSAN VAN METER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.